Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Asset Writedowns and Impairment (2025)

Historic Asset Writedowns and Impairment for Tonix Pharmaceuticals Holding (TNXP) over the last 2 years, with Q3 2025 value amounting to -$962000.0.

  • Tonix Pharmaceuticals Holding's Asset Writedowns and Impairment changed N/A to -$962000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $58.0 million, marking a year-over-year change of. This contributed to the annual value of $59.0 million for FY2024, which is 481308.33% up from last year.
  • According to the latest figures from Q3 2025, Tonix Pharmaceuticals Holding's Asset Writedowns and Impairment is -$962000.0.
  • In the past 5 years, Tonix Pharmaceuticals Holding's Asset Writedowns and Impairment ranged from a high of $59.0 million in Q2 2024 and a low of -$962000.0 during Q3 2025